| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yanhui Chen, Zhongling Ke, Ying Ouyang, Ying Han, Dong Liang, Xueping Gao, Jie He, Yasong D. Clonidine Patch for Tourette Syndrome With Attention-Deficit/Hyperactivity Disorder. Psychiatry investigation. vol 21. issue 4. 2024-05-02. PMID:38695046. |
to explore the efficacy and safety of clonidine adhesive patch in tourette syndrome (ts) patients with comorbid attentiondeficit/hyperactivity disorder (adhd). |
2024-05-02 |
2024-05-04 |
Not clear |
| Stéphane Auvi. A 6-year-old with childhood absence epilepsy and motor hyperactivity. Epilepsy & behavior reports. vol 26. 2024-03-27. PMID:38532901. |
atomoxetine and clonidine, usually use in adhd, lack sufficient data for efficacy and safety in children with epilepsy and adhd. |
2024-03-27 |
2024-03-29 |
Not clear |
| Salam Salloum-Asfar, Nasser Zawia, Sara A Abdull. Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions. Pharmacology & therapeutics. 2023-11-26. PMID:38008401. |
additionally, psychotropic drugs with different mechanisms of action have been approved to reduce associated symptoms and comorbidities, including aripiprazole, risperidone, and haloperidol for irritability and aggression, methylphenidate, atomoxetine, clonidine, and guanfacine for adhd, and melatonin for sleep disturbances. |
2023-11-26 |
2023-11-28 |
Not clear |
| Kathrine Bang Madsen, Thalia K Robakis, Xiaoqin Liu, Natalie Momen, Henrik Larsson, Julie Werenberg Dreier, Helene Kildegaard, Jane Bjerg Groth, Jeffrey H Newcorn, Per Hove Thomsen, Trine Munk-Olsen, Veerle Bergin. In utero exposure to ADHD medication and long-term offspring outcomes. Molecular psychiatry. 2023-02-09. PMID:36759544. |
children of mothers who continued adhd medication (methylphenidate, amphetamine, dexamphetamine, lisdexamphetamine, modafinil, atomoxetine, clonidine) during pregnancy and children of mothers who discontinued adhd medication before pregnancy were compared using cox regression. |
2023-02-09 |
2023-08-14 |
Not clear |
| Jacob T Brow. The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications. Methods in molecular biology (Clifton, N.J.). vol 2547. 2022-09-06. PMID:36068472. |
the most prescribed medications for the treatment of adhd include methylphenidate, mixed amphetamine salts, atomoxetine, guanfacine, and clonidine. |
2022-09-06 |
2023-08-14 |
Not clear |
| Ann Genovese, Trevena Moore, Pete Charlie Haynes, Marilyn Augusty. Interoception in Practice: The Gut-Brain Connection. Journal of developmental and behavioral pediatrics : JDBP. 2022-08-30. PMID:36040816. |
psychotropic medications were risperidone for irritability associated with autism and clonidine extended release for adhd. |
2022-08-30 |
2023-08-14 |
Not clear |
| Keith Mather, Michelle Condre. Extended-Release Viloxazine for Children and Adolescents With Attention Deficit Hyperactivity Disorder. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. vol 27. issue 5. 2022-07-18. PMID:35845566. |
non-stimulant medication therapy for children, adolescents, and young adults with attention-deficit/hyperactivity disorder (adhd) has included alpha 2-agonists (guanfacine and clonidine) as well as a norepinephrine reuptake inhibitor (atomoxetine) for multiple years. |
2022-07-18 |
2023-08-14 |
Not clear |
| Jagdeep Bhullar, Arti Patel, Jaagruthi Chitithoti, Frederick Venter, Theingi Win, Fowrooz Joolha. Clonidine Overdose as an Unusual Cause of Heart Failure. Journal of investigative medicine high impact case reports. vol 10. 2022-06-24. PMID:35748424. |
alpha antagonism in the medulla and the posterior hypothalamus causing a reduction in sympathetic activation allows for clonidine to be used as an effective off-label treatment for attention-deficit/hyperactivity disorder (adhd). |
2022-06-24 |
2023-08-14 |
Not clear |
| Jagdeep Bhullar, Arti Patel, Jaagruthi Chitithoti, Frederick Venter, Theingi Win, Fowrooz Joolha. Clonidine Overdose as an Unusual Cause of Heart Failure. Journal of investigative medicine high impact case reports. vol 10. 2022-06-24. PMID:35748424. |
this is a case of a 28-year-old female with hypertension, adhd, and depression who developed acute heart failure with significant troponemia after ingesting 30 pills of clonidine. |
2022-06-24 |
2023-08-14 |
Not clear |
| Madeleine J Groom, Samuele Cortes. Current Pharmacological Treatments for ADHD. Current topics in behavioral neurosciences. 2022-05-04. PMID:35507282. |
currently approved pharmacological treatments for adhd include a range of stimulant (methylphenidate, amphetamine) and nonstimulant (atomoxetine, guanfacine, clonidine) medications. |
2022-05-04 |
2023-08-13 |
Not clear |
| Veit Roessner, Heike Eichele, Jeremy S Stern, Liselotte Skov, Renata Rizzo, Nanette Mol Debes, Péter Nagy, Andrea E Cavanna, Cristiano Termine, Christos Ganos, Alexander Münchau, Natalia Szejko, Danielle Cath, Kirsten R Müller-Vahl, Cara Verdellen, Andreas Hartmann, Aribert Rothenberger, Pieter J Hoekstra, Kerstin J Plesse. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. European child & adolescent psychiatry. 2021-11-29. PMID:34757514. |
other agents that can be considered include tiapride, risperidone, and especially in case of co-existing attention deficit hyperactivity disorder (adhd), clonidine and guanfacine. |
2021-11-29 |
2023-08-13 |
Not clear |
| Ashish Sarangi, Daniel Payberah, Terry McMaho. The Use of Clonidine in the Treatment of Debilitating Obsessive-Compulsive Behaviors Comorbid With Depression and Post-Traumatic Stress Disorder: A Case Report. Cureus. vol 13. issue 5. 2021-06-15. PMID:34123619. |
clonidine is an alpha-2 agonist traditionally used as an antihypertensive, and more recently in the treatment of psychiatric disorders such as attention-deficit hyperactive disorder (adhd), tic disorders such as tourette's syndrome, and post-traumatic stress disorder (ptsd). |
2021-06-15 |
2023-08-13 |
Not clear |
| Andrew J Cutler, Gregory W Mattingly, Rakesh Jain, Welton O'Nea. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS spectrums. 2021-01-25. PMID:33121553. |
with more than 30 classical schedule ii (cii) stimulant preparations available for adhd treatment, only three nonstimulants (atomoxetine and extended-release formulations of clonidine and guanfacine) have been approved by the united states food and drug administration (fda), all of which focus on modulating the noradrenergic system. |
2021-01-25 |
2023-08-13 |
Not clear |
| Sung Woo Joo, Hyo-Won Ki. Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release. Psychiatry investigation. vol 15. issue 1. 2020-10-01. PMID:29422931. |
we aimed to assess the effectiveness and safety of clonidine extended release (er) treatment in korean youth with adhd and/or tourette's disorder. |
2020-10-01 |
2023-08-13 |
human |
| Michael O Ogundele, Hani F Ayyas. Review of the evidence for the management of co-morbid Tic disorders in children and adolescents with attention deficit hyperactivity disorder. World journal of clinical pediatrics. vol 7. issue 1. 2020-09-30. PMID:29456930. |
level a evidence support the use of alpha adrenergic agonists, including clonidine and guanfacine, reuptake noradrenenaline inhibitors (atomoxetine) and stimulants (methylphenidate and dexamphetamines) for the treatment of tics and comorbid adhd. |
2020-09-30 |
2023-08-13 |
Not clear |
| Ruiling Luan, Zhiling Mu, Fang Yue, Shaoying H. Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Frontiers in psychiatry. vol 8. 2020-09-29. PMID:29180967. |
our study is an analysis of multiple publications involving assessing the comparable efficacy and tolerability of six interventions, which are lisdexamfetamine dimesylate (ldx), atomoxetine (atx), methylphenidate (mph), clonidine hydrochloride (clon), guanfacine extended release (gxr), and bupropion, for young patients (6-18 years old) suffering from attention deficit hyperactivity disorder (adhd). |
2020-09-29 |
2023-08-13 |
Not clear |
| Marisha Agana, Roger Apple, Zakia Alavi, Tyler Gibb, Neelkamal Soares, Marilyn Augusty. Caring for the Transgender Adolescent: It Takes a Village. Journal of developmental and behavioral pediatrics : JDBP. vol 40. issue 5. 2020-08-21. PMID:31107766. |
she was diagnosed with adhd at 12 years and has been placed on methylphenidate and clonidine over the years with little improvement. |
2020-08-21 |
2023-08-13 |
Not clear |
| David Coghil. Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term? (For). Journal of the American Academy of Child and Adolescent Psychiatry. vol 58. issue 10. 2020-08-19. PMID:31515164. |
although randomized controlled trials are the highest level of evidence, most authorities agree that, when you have treatments as efficacious as the adhd medications (methylphenidate and amphetamine derivatives and prodrugs, atomoxetine, guanfacine, and clonidine), it is neither practical nor ethical to conduct long-term placebo-controlled rcts. |
2020-08-19 |
2023-08-13 |
Not clear |
| Shih-Fen Chen, Yuan-Chih Su, Ling-Yi Wang, Chung-Y Hsu, Yu-Chih She. Tourette's syndrome is associated with an increased risk of traumatic brain injury: A nationwide population-based cohort study. Parkinsonism & related disorders. vol 63. 2020-05-08. PMID:30833232. |
the study aimed to determine the risk of tbi in ts patients, the effects associated with concurrent psychiatric disorders (attention-deficit/hyperactivity disorder (adhd), obsessive-compulsive disorder (ocd), or depressive disorder), and the effects of medication treatment (antipsychotics, antidepressants, or clonidine) on the risk of tbi. |
2020-05-08 |
2023-08-13 |
Not clear |
| Thomas B Fay, Martin A Alper. Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder Part 2: Impact on Cardiovascular Events and Recommendations for Evaluation and Monitoring. Cardiology in review. vol 27. issue 4. 2019-12-17. PMID:30531411. |
nonpsychostimulant medications used to treat adhd include atomoxetine and 2 α-2 adrenergic agonists: guanfacine extended-release and clonidine extended-release. |
2019-12-17 |
2023-08-13 |
Not clear |